---
title: "Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Limitations of current therapies"
description: "Formulary evidence on Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Limitations of current therapies. Topics: Summary: limitations of endocrine and targeted therapies after a CDK4/6 inhibitor; Summary: limitations of PARP inhibitors, antibody-drug conjugates, and chemotherapy; ESR1 mutation restriction of oral endocrine therapy: elacestrant label; ESR1 mutation restriction of oral endocrine therapy: imlunestrant label; 21 further topics. 25 evidence topics quoted from 35 sources."
canonical: "https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description/limitations-of-current-therapies"
published: "2026-11-15T20:23:25-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Limitations of current therapies

<a id="heading-2.2.2.1.8"></a>

## 2.2.2.1.8 Limitations of Current Therapies

<a id="topic-2.2.2.1.8-1"></a>

### Summary: limitations of endocrine and targeted therapies after a CDK4/6 inhibitor

The oral estrogen receptor degraders approved after progression on endocrine therapy (elacestrant, imlunestrant, and vepdegestrant) are indicated for ESR1-mutated disease, and each label directs selection of patients “based on the presence of ESR1 mutation(s)” in a plasma specimen. Without ESR1 mutations, the progression-free survival hazard ratio for elacestrant was 0.86 (95% CI 0.63 to 1.19) in 250 participants (52%) in EMERALD, and median progression-free survival in EMBER-3 was 5.6 months with imlunestrant and 5.7 months with standard therapy (hazard ratio 1.00). In ESR1-mutated tumors, the ABC8 consensus describes “modest absolute clinical benefit” across the oral SERDs, with hazard ratios generally in the 0.55 to 0.62 range. In EMERALD, median progression-free survival was 2.8 versus 1.9 months in the overall population and 3.8 versus 1.9 months in the ESR1 mutation cohort. In the control arms of VERITAC-2 and EMBER-3, median progression-free survival was 2.1 months with fulvestrant among 270 participants with ESR1 mutations and 3.8 months with standard therapy among participants with ESR1 mutations, respectively. In real-world studies after a first-line CDK4/6 inhibitor, the weighted average median progression-free survival was 3.9 months with single-agent endocrine therapy and 6.1 months with chemotherapy, and in a second cohort, median second-line real-world progression-free survival with endocrine monotherapy was 5.0 months (n = 27).

Fulvestrant 500 mg is administered as two 5 mL intramuscular injections on Days 1, 15, 29, and once monthly thereafter, and injection site pain was reported in 11.6% of participants in the fulvestrant 500 mg group. Hyperglycemia was reported in 65% of participants treated with alpelisib, and increased fasting glucose occurred in 37% of participants treated with capivasertib and 85% of participants treated with inavolisib; adverse events led to discontinuation in 25.0% of participants receiving alpelisib (4.2% with placebo) and 13.0% of participants receiving capivasertib (2.3% with placebo). Overall survival was not significantly improved with capivasertib plus fulvestrant (hazard ratio 0.83 in the PIK3CA/AKT1/PTEN-altered subgroup), alpelisib plus fulvestrant in the PIK3CA-mutated cohort (39.3 versus 31.4 months), everolimus plus exemestane (31.0 versus 26.6 months), abemaciclib plus fulvestrant (32.1 versus 24.6 months), or imlunestrant in ESR1-mutated disease (34.5 versus 23.1 months, boundary for significance not reached). The ABC8 consensus does not recommend rechallenge with a second oral SERD or a second PI3K/AKT/mTOR inhibitor outside clinical trials, and states that following progression on a CDK4/6 inhibitor “the optimal sequence remains undefined”.

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf); [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf); [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf); [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/); [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/); [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/); [Campone et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40454645/); [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/); [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/); [Faslodex prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf); [Piqray prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212526s011lbl.pdf); [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf); [Itovebi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219249s004lbl.pdf); [André et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31091374/); [Turner et al. (2023)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11335038/); [André et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33246021/); [Piccart et al. (2014)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/); [Kalinsky et al. (2026)](https://pubmed.ncbi.nlm.nih.gov/42926108/); [Jhaveri et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13485152/)

<a id="topic-2.2.2.1.8-2"></a>

### Summary: limitations of PARP inhibitors, antibody-drug conjugates, and chemotherapy

Olaparib and talazoparib are indicated for germline BRCA-mutated, HER2-negative disease, and approximately 5% of all breast cancer patients carry a germline deleterious BRCA1 and/or BRCA2 mutation. Neither improved overall survival significantly over chemotherapy: median overall survival was 19.3 months with olaparib and 17.1 months with chemotherapy (hazard ratio 0.90; 0.86 in hormone receptor-positive participants), and the overall survival hazard ratio with talazoparib was 0.827 in hormone receptor-positive participants. Adjudicated drug-related interstitial lung disease or pneumonitis occurred in 12.1% of participants receiving trastuzumab deruxtecan in DESTINY-Breast04, and adjudicated interstitial lung disease or pneumonitis in 11.3% in DESTINY-Breast06; ocular adverse reactions occurred in 38% of participants treated with datopotamab deruxtecan in the pooled safety population; and grade 3 or higher treatment-related neutropenia occurred in 51% of participants receiving sacituzumab govitecan in TROPiCS-02. Overall survival with datopotamab deruxtecan was not significantly different from chemotherapy (hazard ratio 1.01), and the ABC8 consensus states that routine sequencing of antibody-drug conjugates in this setting “cannot currently be recommended”. In the TROPION-Breast01 control arm, single-agent chemotherapy produced a median progression-free survival of 4.9 months, with grade 3 or higher treatment-related adverse events in 44.7% of participants, and eribulin was not superior to capecitabine for overall survival (median 15.9 versus 14.5 months) or progression-free survival (4.1 versus 4.2 months).

Source: [Lynparza prescribing information (2025)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/208558s031lbl.pdf); [Talzenna prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/211651s014lbl.pdf); [Robson et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6503629/); [Litton et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10649377/); [Modi et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10561652/); [Bardia et al. (2024b)](https://pubmed.ncbi.nlm.nih.gov/39282896/); [Datroway prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/761394s003lbl.pdf); [Rugo et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/36027558/); [Pistilli et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41448362/); [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/); [Bardia et al. (2025)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11771365/); [Kaufman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4463422/)

<a id="topic-2.2.2.1.8-3"></a>

### ESR1 mutation restriction of oral endocrine therapy: elacestrant label

> “Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with ORSERDU based on the presence of ESR1 mutation(s) in plasma specimen using an FDA-authorized test”
> “An exploratory analysis of PFS in the 250 (52%) patients without ESR1 mutations showed a HR 0.86 (95% CI: 0.63, 1.19) indicating that the improvement in the ITT population was primarily attributed to the results seen in the ESR1 mutated population.”

Source: [Orserdu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/217639s007lbl.pdf)

<a id="topic-2.2.2.1.8-4"></a>

### ESR1 mutation restriction of oral endocrine therapy: imlunestrant label

> “Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with INLURIYO based on the presence of ESR1 mutation(s) in a plasma specimen using an FDA-authorized test”
> “a PFS improvement was not demonstrated for INLURIYO monotherapy compared to investigator’s choice of endocrine therapy in either the overall or ESR1m not detected populations, indicating that the benefit for INLURIYO monotherapy was only observed in the ESR1m population.”

Source: [Inluriyo prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218881s001lbl.pdf)

<a id="topic-2.2.2.1.8-5"></a>

### ESR1 mutation restriction of oral endocrine therapy: vepdegestrant label

> “Select patients for treatment of ER-positive, HER2-negative advanced or metastatic breast cancer with VEPPANU based on the presence of ESR1 mutation(s) in plasma specimen using an FDA-authorized test”
> “A statistically significant difference in PFS by BICR was observed for the patients whose tumors had ESR1 mutations for VEPPANU compared with fulvestrant.”

Source: [Veppanu prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219835Orig1s000lbl.pdf)

<a id="topic-2.2.2.1.8-6"></a>

### No progression-free survival difference without ESR1 mutation: EMBER-3

> “In exploratory analyses involving patients without ESR1 mutations, the median progression-free survival was 5.6 months in the imlunestrant group and 5.7 months in the standard-therapy group (hazard ratio for progression or death, 1.00; 95% CI, 0.79 to 1.27)”
> “Among patients with ER-positive, HER2-negative advanced breast cancer, treatment with imlunestrant led to significantly longer progression-free survival than standard therapy among those with ESR1 mutations but not in the overall population.”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.1.8-7"></a>

### Modest absolute benefit of oral SERDs: ABC8 consensus 2026

> “Across this body of evidence, a consistent pattern emerges of modest absolute clinical benefit in ESR1-mutated tumors, with hazard ratios generally in the 0.55–0.62 range.”
> “Rechallenge with one oral SERD after progression on another is not recommended outside clinical trials.”
> “The use of a PI3K/AKT/mTOR inhibitor after progression on another agent of the same class is not recommended outside clinical trials.”
> “As multiple targeted agents are now available following progression on a CDK4/6i, the optimal sequence remains undefined; until prospective comparative data are available, the eligibility criteria of individual trials and the tumor biomarker profile should guide treatment selection.”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.8-8"></a>

### Short progression-free survival with endocrine monotherapy after a CDK4/6 inhibitor: EMERALD control arm

> “Because of the initial drop in PFS in both arms, median PFS may not be a sufficient measure of efficacy in the overall population (2.8 months v 1.9 months) or ESR1 mutation cohort (3.8 months v 1.9 months).”
> “In a recent phase II trial, fulvestrant was associated with a median PFS of 1.9 months and a CBR of 13.7%.”

Source: [Bidard et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9553388/)

<a id="topic-2.2.2.1.8-9"></a>

### Short progression-free survival with fulvestrant after a CDK4/6 inhibitor: VERITAC-2 control arm

> “Patients were required to have disease progression on one to two lines of endocrine therapy, including one line with a CDK4/6 inhibitor.”
> “Median PFS was 5 months (95% CI: 3.7, 7.4) in the vepdegestrant arm and 2.1 months (95% CI: 1.9, 3.5) in the fulvestrant arm (hazard ratio 0.57 [95% CI: 0.42, 0.77]; p-value 0.0001).”
> “OS was immature with 16% of deaths in this population at the time of the PFS analysis.”

Source: [FDA vepdegestrant approval notice (2026)](https://www.fda.gov/drugs/cancer-approvals/fda-approves-vepdegestrant-er-positive-her2-negative-esr1-mutated-advanced-or-metastatic-breast)

<a id="topic-2.2.2.1.8-10"></a>

### Short progression-free survival with standard endocrine therapy: EMBER-3 control arm

> “Among patients with ESR1 mutations, the median progression-free survival was 5.5 months (95% confidence interval [CI], 3.9 to 7.4) in the imlunestrant group, as compared with 3.8 months (95% CI, 3.7 to 5.5) in the standard-therapy group”

Source: [Jhaveri et al. (2025a)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13674379/)

<a id="topic-2.2.2.1.8-11"></a>

### Intramuscular administration of fulvestrant: fulvestrant label

> “The recommended dose of FASLODEX is 500 mg to be administered intramuscularly into the buttocks (gluteal area) slowly (1 - 2 minutes per injection) as two 5 mL injections, one in each buttock, on Days 1, 15, 29, and once monthly thereafter”
> “Injection site related events including sciatica, neuralgia, neuropathic pain, and peripheral neuropathy have been reported with FASLODEX injection.”
> “The most frequently reported adverse reactions in the FASLODEX 500 mg group were injection site pain (11.6% of patients), nausea (9.7% of patients), and bone pain (9.4% of patients)”

Source: [Faslodex prescribing information (2021)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/021344s044lbl.pdf)

<a id="topic-2.2.2.1.8-12"></a>

### Pharmacologic limitations of fulvestrant: review

> “Clinical challenges with fulvestrant can be related to pharmacologic limitations, including the absence of oral bioavailability,”
> “Pharmacologic limitations regarding the bioavailability of fulvestrant have prompted strong interest in an orally bioavailable alternative.”

Source: [Lloyd et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9340905/)

<a id="topic-2.2.2.1.8-13"></a>

### Oral route compared with intramuscular fulvestrant: ABC8 consensus 2026

> “The oral route of administration and generally favorable tolerability of these agents represent meaningful advantages for patients, particularly compared to intramuscular fulvestrant.”
> “Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, showed encouraging PFS results in the VIKTORIA-1 trial, but with a demanding administration schedule and significant stomatitis burden requiring careful management”

Source: [Cardoso et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13697336/)

<a id="topic-2.2.2.1.8-14"></a>

### Hyperglycemia with PI3K inhibition: alpelisib label

> “Severe hyperglycemia, in some cases associated with hyperglycemic hyperosmolar non-ketotic syndrome (HHNKS) or ketoacidosis has occurred in patients treated with PIQRAY.”
> “Hyperglycemia was reported in 65% of patients treated with PIQRAY.”
> “In the 187 patients with hyperglycemia, 87% (163/187) were managed with anti-hyperglycemic medication”

Source: [Piqray prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/212526s011lbl.pdf)

<a id="topic-2.2.2.1.8-15"></a>

### Hyperglycemia with AKT inhibition: capivasertib label

> “TRUQAP can cause severe hyperglycemia, including diabetic ketoacidosis and fatal outcomes.”
> “Increased fasting glucose from baseline occurred in 37% of patients treated with TRUQAP, including 11% of patients with Grade 2 (FG > 160 to 250 mg/dL), 2% with Grade 3 (FG > 250 to 500 mg/dL), and 1.1% with Grade 4 (FG > 500 mg/dL) events.”
> “The safety of TRUQAP has not been established in patients with Type 1 diabetes or Type 2 diabetes that is uncontrolled or requiring insulin at baseline as these patients were excluded from clinical studies”

Source: [Truqap prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/218197s006lbl.pdf)

<a id="topic-2.2.2.1.8-16"></a>

### Hyperglycemia with PI3K-alpha inhibition: inavolisib label

> “Increased fasting glucose occurred in 85% of patients treated with ITOVEBI, including 22% of patients with Grade 2 (FPG > 160 to 250 mg/dL), 12% with Grade 3 (FPG > 250 to 500 mg/dL), and 0.6% with Grade 4 (FPG > 500 mg/dL) events.”
> “In INAVO120, 46% (74/162) of patients who received ITOVEBI were treated with oral anti-hyperglycemic medications and 7% (11/162) were treated with insulin to manage increased fasting glucose.”
> “Hyperglycemia led to dose interruption in 28%, to dose reduction in 2.5%, and to discontinuation of ITOVEBI in 1.2% of patients.”

Source: [Itovebi prescribing information (2026)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/219249s004lbl.pdf)

<a id="topic-2.2.2.1.8-17"></a>

### Short real-world progression-free survival after first-line CDK4/6 inhibitor: US Flatiron cohort

> “Cytotoxic chemotherapy was the most common second-line therapy, followed by endocrine monotherapy, administered to 249 (29.7%) and 104 (12.4%) of patients, respectively.”
> “The median rwPFS for those patients who received chemotherapy, fulvestrant monotherapy, or everolimus were 3.71, 3.25, and 3.32 months, respectively.”

Source: [Martin et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC9177121/)

<a id="topic-2.2.2.1.8-18"></a>

### Short real-world progression-free survival in second and third lines: SOLTI-1801 CDK-PREDICT

> “Median rwPFS-2L was 5.0 months for endocrine monotherapy (n = 27), 7.0 months for targeted therapies (n = 65), 7.4 months for capecitabine (n = 12), and 8.7 months for other chemotherapy agents (n = 21).”
> “In rwPFS-3L, similar trends were seen (6.4 vs. 3.3 months; HR 1.74; 95% CI 0.98–3.08), with BL showing the poorest outcomes (HR 5.63; 95% CI 1.17–27.02).”
> “Endocrine monotherapy was consistently associated with the shortest rwPFS across lines, reinforcing its limited role in this setting.”

Source: [Tolosa et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC12950024/)

<a id="topic-2.2.2.1.8-19"></a>

### Short real-world progression-free survival in second line: systematic review of real-world evidence

> “The most assessed outcome was median rwPFS; the weighted average median rwPFS was calculated as 3.9 months (3.3-6.0 months) for single-agent ET, 3.6 months (2.5–4.9 months) for mTORi ± ET, 3.7 months for a mix of ET and/or mTORi (3.0–4.0 months), and 6.1 months (3.7–9.7 months) for chemotherapy.”
> “no studies reported disaggregated outcomes in the third-line setting or beyond”
> “The real-world effectiveness of current 2 L treatments post-1 L CDK4/6i are suboptimal, highlighting an unmet need for this patient population.”

Source: [Lambert et al. (2024)](https://pmc.ncbi.nlm.nih.gov/articles/PMC11112888/)

<a id="topic-2.2.2.1.8-20"></a>

### Overall survival not statistically improved: EMBER-3 interim overall survival

> “In patients with ESR1m, median OS (mOS) was 34.5 months for imlunestrant versus 23.1 months for SOC [hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.43-0.86, P = 0.0043, boundary for significance not reached].”

Source: [Jhaveri et al. (2026b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13485152/)

<a id="topic-2.2.2.1.8-21"></a>

### Overall survival not statistically improved: PARP inhibitor trials

> “In gBRCA1/2-mutated HER2-negative ABC, talazoparib did not significantly improve OS over chemotherapy, although subsequent treatments may have impacted analysis.”

Source: [Litton et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10649377/)

<a id="topic-2.2.2.1.8-22"></a>

### Overall survival not statistically improved: datopotamab deruxtecan

> “While there was no statistically significant improvement in the dual primary endpoint of OS with Dato-DXd versus ICC, subsequent ADC treatment may have affected OS results.”

Source: [Pistilli et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/41448362/)

<a id="topic-2.2.2.1.8-23"></a>

### Overall survival not statistically improved: eribulin versus capecitabine

> “In this phase III study, eribulin was not shown to be superior to capecitabine with regard to OS or PFS.”

Source: [Kaufman et al. (2015)](https://pmc.ncbi.nlm.nih.gov/articles/PMC4463422/)

<a id="topic-2.2.2.1.8-24"></a>

### Inevitable endocrine resistance and uncertain sequencing: reviews

> “Endocrine resistance inevitably develops in the metastatic setting, often mediated by acquired ESR1 mutations that promote ligand-independent ER activation and reduce sensitivity to standard antiestrogens.”
> “Their optimal integration and sequencing in practice remain uncertain, and for tumors harboring dual ESR1 and PIK3CA mutations, with multiple biomarker-guided options available, the best treatment strategies are unclear.”
> “With several oral SERDs emerging contemporaneously, data are needed to assess their relative efficacy, safety, and potential interchangeability.”

Source: [Lloyd et al. (2026b)](https://pubmed.ncbi.nlm.nih.gov/42413061/)

<a id="topic-2.2.2.1.8-25"></a>

### Resistance to anti-oestrogen therapy: review

> “Resistance to anti-oestrogen agents inevitably occurs, mediated by oestrogen receptor (ER)-dependent or ER-independent mechanisms that drive tumour progression.”

Source: [Lloyd et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/39179659/)

## Related pages
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Terms and abbreviations](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/terms-and-abbreviations.md)
- [Palazestrant (OP-1250): Previously treated ER-positive HER2-negative advanced or metastatic breast cancer](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/executive-summary.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Product information and disease description](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/product-information-and-disease-description.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Clinical evidence](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/clinical-evidence.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: Economic information and modeling report](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/economics.md)
- [Palazestrant (OP-1250) in Previously treated ER-positive HER2-negative advanced or metastatic breast cancer: References](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references) · [Markdown](https://www.evicenter.com/drugs/palazestrant--previously-treated-er-positive-her2-negative-advanced-or-metastatic-breast-cancer/references.md)
